Alx oncology to host virtual company event highlighting updated data from aspen-06 phase 2 trial presented at 2025 asco gi

South san francisco, calif., jan. 21, 2025 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on thursday, january 23, at 1:00 p.m. pt/4:00 p.m. et to discuss updated data from the aspen-06 phase 2 clinical trial evaluating the company's investigational cd47-blocker evorpacept in patients with previously treated her2-positive advanced gastric cancer (gc) or gastroesophageal junction (gej) cancer.
ALXO Ratings Summary
ALXO Quant Ranking